# US 9,517,237 B2 · Compounds and methods for treating multiple sclerosis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,517,237 B2 - Document ID: US9517237B2 - Status: Granted - Kind: B2 - Application number: 14/706,300 - Filed: 2015-05-07 - Published: 2015-09-03 - Granted: 2016-12-13 - Earliest claimed: 2010-11-10 - Assignees: Purdue Research Foundation - Applicants: Neuro Vigor, LLC - Inventors: Riyi Shi - Web page: https://patentgrep.com/patent/US9517237B2 ## CPC - A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} - A61K 31/50: Pyridazines; Hydrogenated pyridazines - A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention described herein pertains to the treatment of multiple sclerosis. In particular, the invention described herein pertains to the treatment of multiple sclerosis using compounds that modulate the action of acrolein. ## Claims ### Claim 1 A composition comprising a fused hydrazinopyridazine in a therapeutically effective amount for treating a patient with multiple sclerosis, wherein the amount is at least about 2-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 2 (depends on 1) The composition according to claim 1, wherein the amount is at least about 3-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 3 (depends on 1) The composition according to claim 1, wherein the amount is at least about 4-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 4 (depends on 1) The composition according to claim 1, wherein the amount is at least about 5-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 5 (depends on 1) The composition according to claim 1, wherein the amount is at least about 10-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 6 (depends on 1) The composition according to claim 1, wherein the amount is at least about 20-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 7 (depends on 1) The composition according to claim 1, wherein the amount is at least about 30-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 8 (depends on 1) The composition according to claim 1, wherein the amount is at least about 50-fold lower than a therapeutically effective amount for treating hypertension. ### Claim 9 (depends on 1) The composition according to claim 1, wherein the therapeutically effective amount for treating a patient with multiple sclerosis is at most about 5 milligrams. ### Claim 10 (depends on 1) The composition according to claim 1, wherein the fused hydrazinopyridazine is a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein: R is independently selected in each instance from hydrogen, acyl, or sulfonyl; or alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and RA represents three substituents, one of which is selected from the group consisting of hydrogen, halo, hydroxy and derivatives thereof, amino and derivatives thereof, thio and derivatives thereof, acyl, carboxylate or a derivative thereof, hydroxylamino and derivatives thereof, hydrazino and derivatives thereof, sulfonyl or a derivative thereof, or sulfonyl or a derivative thereof; or alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heteroalkyl, heteroalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and two of RA are taken together with the attached carbons to form an optionally substituted saturated, unsaturated, or aromatic carbocycle or heterocycle. ### Claim 11 (depends on 10) The composition according to claim 10, wherein RA represents a hydrogen; or RA includes an optionally substituted benzo group; or RA includes an optionally substituted fused piperidine; or RA includes a hydrazino or derivative thereof; or RA includes a hydrazino; or RA includes amino or a derivative thereof; or RA includes dialkylamino, where each alkyl is independently selected, and independently optionally substituted. ### Claim 12 (depends on 10) The composition according to claim 10, wherein each R is hydrogen; or at least one R is acyl; or at least one R is optionally substituted alkoxycarbonyl. ### Claim 13 (depends on 12) The composition according to claim 12, wherein each R is hydrogen. ### Claim 14 (depends on 12) The composition according to claim 12, wherein at least one R is acyl. ### Claim 15 (depends on 12) The composition according to claim 12, wherein at least one R is optionally substituted alkoxycarbonyl. ### Claim 16 (depends on 1) The composition according to claim 1, wherein the fused hydrazinopyridazine is hydralazine. ### Claim 17 (depends on 1) The composition according to claim 1, wherein the composition is formulated for oral administration. ### Claim 18 (depends on 1) The composition according to claim 1, wherein the composition is formulated as a single unit dosage. ### Claim 19 (depends on 17) The composition according to claim 17, wherein the composition is formulated as a divided unit dosage.